Illumina, Inc.’s Stock Price Plummets to $112.82, Experiencing a Significant 5.18% Drop

Illumina, Inc. (ILMN)

112.82 USD -6.16 (-5.18%) Volume: 2.95M

Illumina, Inc.’s stock price is currently at 112.82 USD, experiencing a dip of -5.18% this trading session with a trading volume of 2.95M. The company’s stock has seen a significant decline YTD with a percentage change of -18.97%, indicative of its volatile performance in the market.

Latest developments on Illumina, Inc.

Following a turbulent week, Illumina Inc‘s stock price experienced significant movements. The week started with a slump as Illumina’s stock underperformed on Tuesday compared to its competitors. However, the company made a strategic move by filing a Form 10 registration statement, preparing for its planned divestiture of GRAIL. This sparked a positive reaction in the market, leading to a rise in the stock price on Monday, despite still underperforming the market. Yet, the stock was later downgraded to ‘Hold’ by StockNews.com, while its price target was lowered to $176.00, after previously being raised to $128.00 by Robert W. Baird.

Illumina, Inc. on Smartkarma

Analysts at Baptista Research have been closely covering Illumina Inc on Smartkarma, providing valuable insights into the company’s performance and future prospects. In their report titled “Illumina Inc: Will Its Market Dominance In Genetic Analysis Last In The Long Term? – Major Drivers,” they highlight the company’s successful 2023 but caution about challenges in 2024 due to macroeconomic hurdles. CEO Jacob Thaysen praised the latest product, NovaSeq X, as the most successful high-throughput product launch in the company’s history.

Another report by Baptista Research, titled “Illumina Inc: The Inside Story of Steady Revenues and Strategic Expansions! – Major Drivers,” discusses how Illumina delivered mixed results in the previous quarter, with revenues below analyst consensus. Despite lower revenue, non-GAAP net income exceeded expectations. The report also notes a decline in Core Illumina sequencing consumables revenue but a growth in clinical sequencing consumables, which helped offset the overall decline.

A look at Illumina, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Illumina Inc has a mixed long-term outlook. While the company scores moderately in terms of value and momentum, it lags behind in dividend, growth, and resilience. This suggests that while Illumina Inc may offer some value and show positive momentum, investors should be cautious about its growth potential, dividend payouts, and ability to withstand market fluctuations.

Illumina Inc is a company that focuses on developing, manufacturing, and marketing integrated systems for genetic analysis. With a comprehensive line of products and services catering to various markets in genomic research, pharmaceuticals, academia, and biotechnology, Illumina Inc plays a vital role in advancing genetic variation and biological function analysis. However, its Smartkarma Smart Scores indicate areas of improvement needed for the company to secure a more stable long-term outlook.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma